Bristol/Astra change-in-control
Executive Summary
Bristol-Myers Squibb's codevelopment and commercialization agreement with AstraZeneca for two diabetes compounds does not include change-in-control provisions, Bristol CFO Andrew Bonfield says during a Jan. 25 earnings call. Bristol has been rumored to be an acquisition candidate since the launch of Plavix generics, although the AstraZeneca partnership, announced Jan. 11, suggests that the firm plans to remain independent (1"The Pink Sheet" Jan. 15, 2007, p. 16)...
You may also be interested in...
Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.